+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07745504

Comparing Two Injectable Forms of Cagrilintide to Placebo for Weight Management in Adults With Overweight or Obesity

Led by Novo Nordisk A/S · Updated on 2026-09-04

285

Participants Needed

36

Research Sites

7 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how well a new injectable medicine called cagrilintide helps adults with excess body weight to lose weight. This phase 3 trial compares two different presentations of cagrilintide to placebo in people with overweight or obesity. The purpose is to understand the relative change in body weight from the start of treatment to the end of 26 weeks of treatment. Participants will be randomly assigned to one of three groups receiving weekly subcutaneous injections for 26 weeks one group receives cagrilintide with placebo matched to semaglutide in one device and placebo matched to cagrilintide in another another group receives cagrilintide in one device with matched placebos in the other and the last group receives matched placebos in both devices. This double-blind study uses devices for administration and treatment allocation is random. During the study, participants will have regular assessments including measurements of body weight and monitoring for adverse events from the start through 33 weeks. The main outcome measured is the relative change in body weight after 26 weeks of treatment. Safety is also monitored by counting any treatment-emergent adverse events or serious adverse events. Participants are involved for about 9 months in total.

CONDITIONS

Brief Title

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

Research Team

N

Novo Nordisk

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here